KalVista Pharmaceuticals (KALV) Net Equity Issued and Repurchased (2015 - 2021)

KalVista Pharmaceuticals (KALV) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $208.9 million in Q2 2021.

• For the quarter ending Q2 2021, Net Equity Issued and Repurchased changed N/A year-over-year to $208.9 million; the trailing twelve-month figure through Jul 2025 stood at $208.9 million (changed N/A YoY), and the FY2025 full-year result was $55.9 million, down 42.33% from the prior year.
• Net Equity Issued and Repurchased rose to $208.9 million in Q2 2021, from $11.4 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $208.9 million in Q2 2021 to a low of $37000.0 in Q2 2018.
• A 3-year average of $51.4 million and a median of $8.2 million in 2018 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 167.57% in 2019, while the deepest fall reached 128.44% in 2019.
• Tracing KALV's Net Equity Issued and Repurchased over 3 years: stood at $82.8 million in 2018, then tumbled by 86.21% to $11.4 million in 2019, then jumped by 1729.22% to $208.9 million in 2021.
• Business Quant data shows KALV's Net Equity Issued and Repurchased at $208.9 million in Q2 2021, $11.4 million in Q3 2019, and $99000.0 in Q2 2019.